strong>Prima Biomed Ltd., of Sydney, reported that data from the phase II CAN-003 ovarian cancer trial, testing autologous cancer vaccine Cvac, has shown a trend for a clinically meaningful improvement in overall survival (OS) over standard of care in second remission patients.